Mesenchymal stem cells therapy facilitates donor lung preservation by reducing oxidative damage during ischemia

PACIENZA, N *; SANTA CRUZ, DM *; MALVICINI, RICARDO; ROBLEDO, O; LEMUS, G; BERTOLOTTI, A; MARCOS, M; YANNARELLI, G; *ESTOS AUTORES CONTRIBUYERON IGUALMENTE A ESTE TRABAJO

Stem Cells International

Hindawi

Año: 2019

Lung transplantation is a lifesaving therapy for people living with severe, lifethreateninglung disease. The high mortality rate among patients awaitingtransplantation is mainly due to the low percentage of lungs that are deemedacceptable for implantation. Thus, the current shortage of lung donors may besignificantly reduced by implementing different therapeutic strategies whichfacilitate both organ preservation and recovery. Here, we studied whether theanti-inflammatory effect of human umbilical cord-derived mesenchymal stemcells (HUCPVCs) increases lung availability by improving organ preservation. Wedeveloped a lung preservation rat model that mimics the different stages bywhich donor organs must undergo before implantation. The therapeutic schemawas as follows: cardiac arrest, warm ischemia (2h at room temperature), coldischemia (1.5h at 4°C, with Perfadex), and normothermic lung perfusion withventilation (Steen solution, 1h). After 1h of warm ischemia, HUCPVCs (1x106cells) or vehicle were infused via the pulmonary artery. Physiologic data(pressure-volume curves) were acquired right after the cardiac arrest and at theend of the perfusion. Interestingly, although lung edema did not change amonggroups, lung compliance dropped a 34% in the HUCPVCs-treated group, whilethe vehicle group showed a stronger reduction (69%, p